1Janssen Scientific Affairs, LLC, Raritan, NJ, USA.
J Atten Disord. 2014 Feb;18(2):95-104. doi: 10.1177/1087054712443411. Epub 2012 May 24.
To explore treatment response to Osmotic Release Oral System(®) (OROS) methylphenidate in children with ADHD with and without comorbid learning disability (LD).
Data were analyzed from two 6-week, double-blind, randomized, placebo-controlled, crossover studies evaluating individually determined doses of OROS methylphenidate versus placebo in 135 children (ages 9 to 12 years) with ADHD with or without an LD in reading, math, or both. The sample was demographically diverse, with 31% females and more than 40% minority, predominantly African American and Hispanic. On two laboratory school days, participants received either OROS methylphenidate or placebo and were given a battery of cognitive and behavioral tests.
Treatment with OROS methylphenidate led to improvement in ADHD Rating Scale scores for participants with or without comorbid LD. Both groups performed better during treatment with OROS methylphenidate than placebo on measures of cognitive skills (i.e., Test of Variables of Attention, Finger Windows Backwards), academically related tasks (i.e., Dynamic Indicators of Basic Early Literacy Skills, Test of Handwriting Skills-Revised, Permanent Product Math Test), and observed classroom behavior (i.e., Swanson, Kotkin, Alger, M-Flynn, and Pelham Scale).
In children with ADHD with or without comorbid LD, behavior and performance improved during treatment with OROS methylphenidate.
探究伴有和不伴有共患学习障碍（LD）的 ADHD 儿童对奥昔哌汀控释片（OROS）哌甲酯治疗的反应。
对两项为期 6 周、双盲、随机、安慰剂对照、交叉研究的数据进行了分析，这些研究评估了在 135 名伴有或不伴有阅读、数学或两者均有 LD 的 ADHD 儿童中，根据个体确定剂量的 OROS 哌甲酯与安慰剂相比的疗效。该样本具有多种人口统计学特征，其中 31%为女性，超过 40%为少数民族，主要为非裔美国人和西班牙裔。在两个实验室学校日，参与者接受 OROS 哌甲酯或安慰剂治疗，并接受一系列认知和行为测试。
奥昔哌汀控释片治疗可改善伴有或不伴有共患 LD 的 ADHD 评分量表评分。两组在接受 OROS 哌甲酯治疗时的认知技能（即，变量测试注意力，手指窗口向后）、与学业相关的任务（即，动态基本早期读写技能指标，笔迹技能修订测试，永久产品数学测试）和观察到的课堂行为（即，斯旺森，科特金，阿尔杰，M-弗林，佩勒姆量表）上的表现均优于安慰剂。
在伴有或不伴有共患 LD 的 ADHD 儿童中，行为和表现在接受 OROS 哌甲酯治疗期间得到了改善。
